Skip to content
Abierto
Menu

Award notice

Oral Mucosal Vaccine for SARS-CoV2 Protection

75A50124C00002

Office of Assistant Secretary for Preparedness and Response, Aspr Administration for Strategic Preparedness and Response.

View on SAM.govMarkdown

Awarded

Vaxart Biosciences Inc.

$9,271,193.00 on the award notice, January 12, 2024, contract 75A50124C00002

Description

As published on SAM.gov.

Oral Covid-19 XBB vaccine candidate as a/an tableted prophylactic vaccine for the treatment of SARS-CoV2. The scope of work for this contract encompasses the completion of the planning of and preparation for a phase 2b clinical trial.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Vaxart Biosciences Inc.
UEI
WS6UMD1QTBC9
CAGE
4GQK7
Vendor location
South San Francisco, CA
Contract
75A50124C00002, definitive contract
Obligated
$9,271,191.00
Actions
4 between January 12, 2024 and February 2, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Clinical Trial Planning Activities for a Phase 2B Clinical Trial That Compares Vaxart'S XBB Vaccine Candidate to an Mrna Comparator to Evaluate Efficacy for Symptomatic and Asymptomatic Disease, Systemic and Mucosal Immune Induction, and Adverse
Match
award number 75A50124C00002 equals the contract number; same sub-agency 7505 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. January 13, 2024

    Award notice

    Awarded to VAXART BIOSCIENCES Inc. South San Francisco for $9,271,193. SAM.gov, notice c9e655fc3c514e6da562fa02948a4a6b

Points of contact

Also open from this buyer